Amgen (AMGN) Income from Continuing Operations (2009 - 2026)
Amgen (AMGN) posted quarterly Income from Continuing Operations of 1819000000.0 for Q1 2026, up 5.14% year-over-year from 1730000000.0 in Q1 2025, and up 36.46% quarter-over-quarter from 1333000000.0 in Q4 2025.
Amgen (AMGN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Amgen's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1819000000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 5.14% year-over-year to 1819000000.0; the TTM figure through Mar 2026 stood at 7800000000.0 (up 31.47% YoY), while the FY2025 annual figure was 7711000000.0, up 88.53% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1819000000.0, up from 1333000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3216000000.0 in Q3 2025, with the low at 113000000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 1476000000.0 (2022), against an average of 1581705882.35.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 103.98% in 2024, then jumped 1630.97% in 2025.
- Amgen's Income from Continuing Operations stood at 1616000000.0 in 2022, then sank by 52.54% to 767000000.0 in 2023, then fell by 18.25% to 627000000.0 in 2024, then surged by 112.6% to 1333000000.0 in 2025, then jumped by 36.46% to 1819000000.0 in 2026.
- Business Quant data shows AMGN's Income from Continuing Operations at 1819000000.0 in Q1 2026, 1333000000.0 in Q4 2025, and 3216000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.38 Bn |
| Mar 31, 2026 | 1.82 Bn |
| Dec 31, 2025 | 1.33 Bn |
| Sep 30, 2025 | 3.22 Bn |
| Jun 30, 2025 | 1.43 Bn |
| Mar 31, 2025 | 1.73 Bn |
| Dec 31, 2024 | 627.00 Mn |
| Sep 30, 2024 | 2.83 Bn |
| Jun 30, 2024 | 746.00 Mn |
| Mar 31, 2024 | -113.00 Mn |
| Dec 31, 2023 | 767.00 Mn |
| Sep 30, 2023 | 1.73 Bn |
| Jun 30, 2023 | 1.38 Bn |
| Mar 31, 2023 | 2.84 Bn |
| Dec 31, 2022 | 1.62 Bn |
| Sep 30, 2022 | 2.14 Bn |
| Jun 30, 2022 | 1.32 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.90 Bn |
| Sep 30, 2021 | 1.88 Bn |